Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 142 Publications

20 Customer Reviews

  • Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

    Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  •  

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

    Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MXrDfZRwfG:6aXOgRZN{[Xl? NVK4dY53PTBizszN M2jSOFQ5KGh? NH;3WJhFVVOR MofjT4ltdHNiY3XscJMh[nlibX;y[UB1cGGwIEm5KS=> MXexNFQ6QTZ2Mx?=
OVCA 429 MVrGeY5kfGmxbjDBd5NigQ>? MV:zNFAhdk1? MWC0PEBp MU\EUXNQ NHnwbHRFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM> MkHDNVA6QTl5Nk[=
RPMI8226 Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{myUFExOCCwTR?= MYq0PEBp MXTEUXNQ M{TkbmlEPTB;M{Cgcm0> NHXzbHQyOTNyNkS4PS=>
Dox40 MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv3NVAxKG6P NGToRWE1QCCq MX\EUXNQ NVy3ZmxwUUN3ME20NEBvVQ>? M2nJ[lEyOzB4NEi5
MR20 NHjQcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXRe2QyODBibl2= M3L3eFQ5KGh? NYj2SI0zTE2VTx?= NVXwfIZuUUN3ME2yNEBvVQ>? MmHTNVE{ODZ2OEm=
LR5 Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\UcmEyODBibl2= NHz3S4U1QCCq NYnES21uTE2VTx?= MYDJR|UxRTJyIH7N NIHUXoYyOTNyNkS4PS=>
U266 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj3[GgyODBibl2= Mlf6OFghcA>? NUSyTXBbTE2VTx?= NXzrN|E6UUN3ME2zJI5O NUnTR|dROTF|ME[0PFk>
IM-9 M2f2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCxNFAhdk1? MYS0PEBp NWL3T4E6TE2VTx?= MWnJR|UxRTZibl2= MY[xNVMxPjR6OR?=
Hs Sultan MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrrd5oyODBibl2= NUXpVHN7PDhiaB?= M3\SfWROW09? MX\JR|UxRTJyIH7N MlrhNVE{ODZ2OEm=
PAM-LY2 NYTz[3pmTnWwY4Tpc44hSXO|YYm= M4CwSVExOCCwTR?= Ml61NVIhcA>? NVva[ZhPTE2VTx?= MkG5TY5pcWKrdIOgUmYu|rqEIHHjeIl3[XSrb36= M2WwbFEyOzVyOUGz
PAM 212 NF6ycIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\Le|ExOCCwTR?= M4LOdFczKGh? M2K1R2ROW09? Ml3MTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NHPrPFcyOTN3MEmxNy=>
PAM-LY2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL5OFkyODBibl2= MlvKO|IhcA>? M{fibmROW09? M2\uVWlvcGmkaYTzJINmdGxidnnhZoltcXS7 MUGxNVM2ODlzMx?=
B4B8 NEDQdolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7FTpdJOTByIH7N M132VFczKGh? MmLnSG1UVw>? MnroTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M2WxU|EyOzVyOUGz
B7E3 MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XFVVExOCCwTR?= NHO2XVM4OiCq MlrPSG1UVw>? M13BdmlvcGmkaYTzJINmdGxidnnhZoltcXS7 NFTBOmwyOTN3MEmxNy=>
UM-SCC-9 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG2NVAxKG6P MWi3NkBp MoLrSG1UVw>? MnrqTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M4HFcVEyOzVyOUGz
UM-SCC-11B Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK3UWlYOTByIH7N NEDycZU4OiCq MnTXSG1UVw>? MXTJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MVOxNVM2ODlzMx?=
H460 NIn1OJNHfW6ldHnvckBCe3OjeR?= NYrzcZNNOTBizszN NFnrRnkzPCCq MoT4SG1UVw>? MmrDTY5lfWOnczDCZ4wuOiCyaH;zdIhwenmuYYTpc44h[W6mIHPs[YF3[WenIHPvdpJmdGG2ZXSge4l1cCCJMj3NJJBp[XOnIHHydoV{fA>? MmPlNVI1QTJzMUe=
U266 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLiOVAxKG6pL33s NYntVXRDPDhiaB?= M2fRW2ROW09? MUPJcohq[mm2czDj[YxtKGe{b4f0bC=> NFGzVZMyOjZ|MU[xPS=>
ARH77 NV\MXmxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fCWFUxOCCwZz;tcC=> NHv2[Gk1QCCq MUDEUXNQ M4XK[2lvcGmkaYTzJINmdGxiZ4Lve5Rp NH\FOpcyOjZ|MU[xPS=>
WAD-1 NILyc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHNOnhtPTByIH7nM41t NWDFVZZqPDhiaB?= NXjTXJB{TE2VTx?= MkexTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NW\reVBsOTJ4M{G2NVk>
U266/LR7 MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWS1NFAhdmdxbXy= MVq0PEBp NUS2bVExTE2VTx?= MXPJcohq[mm2czDj[YxtKGe{b4f0bC=> MX[xNlY{OTZzOR?=
U266/dox4 MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P5e|UxOCCwZz;tcC=> MVy0PEBp MmPkSG1UVw>? MkDmTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NUTZU493OTJ4M{G2NVk>
RPMI8226/LR5 NE\UN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[1NFAhdmdxbXy= M3\SbFQ5KGh? MmnoSG1UVw>? MVzJcohq[mm2czDj[YxtKGe{b4f0bC=> NWrxOWJROTJ4M{G2NVk>
H460 NFXvNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[xNEDPxE1? M{TWb|czKGh? NVvsNFduTE2VTx?= MkTyTWM2OD1zMECgcm0> M3y5SFEzPjNzNkKw
H358 NUX1UIY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P0U|ExKM7:TR?= MXO3NkBp MVnEUXNQ MUnJR|UxRTdyIH7N NXn0dHozOTJ4M{G2NlA>
H322 NWTHfIt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDTcWxxOTBizszN MYq3NkBp MlzDSG1UVw>? NUnye29VUUN3ME22NlAhdk1? MmXKNVI3OzF4MkC=
H460 NWnwdXhkTnWwY4Tpc44hSXO|YYm= NXTFNXIxOTByIH7N NHHTT|czPCCq MkPNSG1UVw>? MlrETY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>? NInGWlEyOjZ|MU[yNC=>
LNCap-Pro5 NXK2d|RyTnWwY4Tpc44hSXO|YYm= MlH4NUDPxE1? MWK0JIg> NGTTdndFVVOR M2DqV3N1[WKrbHn6[ZMheDV| NXzZSGJbOTR4MUK1N|I>
T29 NF;RWZlCeG:ydH;zbZMhSXO|YYm= MYi1NEBvVQ>? M1vnXlQ5KGhi M3HRcWROW09? Ml;oTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MYKxOlc4QDF5OR?=
T29Kt1 MWjBdI9xfG:|aYOgRZN{[Xl? NUnpSmc4PTBibl2= NYnCR2htPDhiaDC= M3HXXGROW09? Mm\oTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MojqNVY4PzhzN{m=
HCT116 MYjBdI9xfG:|aYOgRZN{[Xl? NV[xZmtVPTBibl2= NIHvWnQ1QCCqIB?= MW\EUXNQ M4S4WWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MWCxOlc4QDF5OR?=
HKe-3 M{HEdGFxd3C2b4Ppd{BCe3OjeR?= NWiyTFBNPTBibl2= NIr2O3Y1QCCqIB?= NEmyVVlFVVOR MYXJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NI\ER3oyPjd5OEG3PS=>
NB-1691 NF2z[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjBRWYyKM7:TR?= M1TWNlczKGh? MnTxTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDVn M1TPdlE4Pjh7Nki0
CHLA-255 MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrCNUDPxE1? MUO3NkBp MVLJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV? NUnUWFBnOTd4OEm2PFQ>
SK-N-AS M2PZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjISHMyKM7:TR?= NV7BbpZqPzJiaB?= NV3PTGtRUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEGwKS=> M{D4ZlE4Pjh7Nki0
NB-1691 M3j5e2Z2dmO2aX;uJGF{e2G7 M2Dzd|ExKG6P NUfQXldUOjRiaB?= MkXKV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHzzJIlvKHSqZTDHNE9IOSCyaHHz[S=> NGTuOpcyPzZ6OU[4OC=>
CHLA-255 MVrGeY5kfGmxbjDBd5NigQ>? NHH2WYQyOCCwTR?= NHn5V2czPCCq M3K0WW1w\GW|dHz5JJJm\HWlZYOgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOn NEjpTIsyPzZ6OU[4OC=>
RPMI 8226 MWnGeY5kfGmxbjDBd5NigQ>? MWeyNEBvVQ>? NIDZNVA5KGh? MUXTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NGexd4cyQTR|NkC1NC=>
MM.1S M3nyeGZ2dmO2aX;uJGF{e2G7 M4DXN|IxKG6P M4nB[|ghcA>? NWHPeVFLW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MVKxPVQ{PjB3MB?=
U266 Ml;4SpVv[3Srb36gRZN{[Xl? NXnuSo1vOjBibl2= M4jhblghcA>? MXPTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MUOxPVQ{PjB3MB?=
OPM1 MknTSpVv[3Srb36gRZN{[Xl? MmO0NlAhdk1? MlvIPEBp M3u3VnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MoDTNVk1OzZyNUC=
INA6 MV;GeY5kfGmxbjDBd5NigQ>? M{XyS|IxKG6P M4rBcVghcA>? M{S0T3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NFTvc|gyQTR|NkC1NC=>
OPM2 M1ftOmZ2dmO2aX;uJGF{e2G7 M4i4WlIxKG6P Mnm2PEBp MVXTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MXKxPVQ{PjB3MB?=
RPMI 8226 NVjtZZhmTnWwY4Tpc44hSXO|YYm= M4TP[lIxKG6P Ml;nPEBp M4DPe2lv\HWlZYOgSG5CKHO7boTo[ZNqew>? NF\qNHcyQTR|NkC1NC=>
BaF/3 MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL3[5AyODBibl2= NIjtTGY1QCCq MkPPTWM2OD14LkKgcm0> NVu2eoF6OjB|MEW2PVI>
BaF/3-p210 NILJOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnCNVAxKG6P M4i4[FQ5KGh? M3z5U2lEPTB;ND63JI5O M{\NOlIxOzB3Nkmy
TCC-S M3;tXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTLV5QyODBibl2= MX[0PEBp Mmn1TWM2OD1{Lkigcm0> M1\SfVIxOzB3Nkmy
BaF/3 NHHKb5dHfW6ldHnvckBCe3OjeR?= MVG2JI5O M4nDUlQ5KGh? NV;ufnVFUW6mdXPld{BiKGe{ZXH0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 M3TKTlIxOzB3Nkmy
BaF/3-p210 M{nNeWZ2dmO2aX;uJGF{e2G7 NVG4TVBuPiCwTR?= M36wfVQ5KGh? M4jPfGlv\HWlZYOgZUB{dGmpaISgS|Eh[2WubD3jfYNt\SCjcoLld5Q> NYHlUYVpOjB|MEW2PVI>
BaF/3-p210 M3T2cGZ2dmO2aX;uJGF{e2G7 NUWzUWt3PiCwTR?= M{X5UlI1KGh? M3\QdnJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKk NH3JNZMzODNyNU[5Ni=>
Raji NEjkN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzyNUDPxE1? NETLWVIzPCCq NIrDNlZT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NYmyWIZWOjFzN{C5PFg>
LCL-1 Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm4NUDPxE1? MV[yOEBp MVvS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MUGyNVE4ODl6OB?=
LCL-2 NITkcVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nZ[|Eh|ryP MkLHNlQhcA>? NE[1cFRT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MkTFNlEyPzB7OEi=
BJAB NFXmWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\3NUDPxE1? MYOyOEBp MnT1VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NXLxZoM4OjFzN{C5PFg>
SNT-13 NXyzOXZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjJNlQ5OSEQvF2= NVf2d2VZOjRiaB?= MWDS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NWLHXnFiOjFzN{C5PFg>
SNT-16 MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOxJO69VQ>? MlrmNlQhcA>? NET3O3NT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NFz5ZXYzOTF5MEm4PC=>
Jurkat NVPTWotLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MontNUDPxE1? M4nMTFI1KGh? MlnlVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MmHBNlEyPzB7OEi=
KAI-3 NVvhW4M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT6[20yKM7:TR?= NF3j[mYzPCCq MmezVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M4\xd|IyOTdyOUi4
SNK-6 NUXWUWVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LjUlEh|ryP M2PaVlI1KGh? NF[0U4hT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MkTKNlEyPzB7OEi=
KHYG-1 NHP1S49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKxJO69VQ>? MYGyOEBp M2CwSXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MkPRNlEyPzB7OEi=
SNT-16 MnW4RZBweHSxc3nzJGF{e2G7 MVuxJO69VQ>? NV;iW|UzPiCq MV;JcoR2[2W|IHPlcIwh[XCxcITvd4l{ MmX6NlEyPzB7OEi=
Jurkat NVvTeYpISXCxcITvd4l{KEG|c3H5 MnL5NUDPxE1? MV:2JIg> NXnCO4ZGUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M37z[VIyOTdyOUi4
KAI-3 MV;BdI9xfG:|aYOgRZN{[Xl? Mkn2NUDPxE1? MmfPOkBp MX7JcoR2[2W|IHPlcIwh[XCxcITvd4l{ NI\P[4MzOTF5MEm4PC=>
KHYG-1 NECxV2FCeG:ydH;zbZMhSXO|YYm= NF\IVGUyKM7:TR?= M2fPOlYhcA>? M4PGfWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MYeyNVE4ODl6OB?=
SNT-13 MVjBcpRqfmm{YXygRZN{[Xl? NXHDN2ZtOSEQvF2= M1LiUFI1KGh? M{TMbWlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? Ml2wNlEyPzB7OEi=
SNT-16 MVzBcpRqfmm{YXygRZN{[Xl? NWnnO2VGOSEQvF2= NIjYN3ozPCCq NH3SU3dKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NFmyToQzOTF5MEm4PC=>
KAI-3 NYDVU4t4SW62aY\pdoFtKEG|c3H5 M17HUVEh|ryP NYD5UGVYOjRiaB?= MWPJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> M37hflIyOTdyOUi4
SNK-6 Mor6RY51cX[rcnHsJGF{e2G7 M2K4ZlEh|ryP MkS4NlQhcA>? MnvGTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX Mn31NlEyPzB7OEi=
RAW 264.7 M3XPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmWwNVAxKG6P MUW0PEBp MWDS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MkjpNlI1OjdzNUS=
A375 NInSNItCeG:ydH;zbZMhSXO|YYm= MVGxNEBvVQ>? M1vu[VI1KGh? NIrweIxKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NGfwcYQzOzB5OUC4Ny=>
BLM MVjBdI9xfG:|aYOgRZN{[Xl? MWixNEBvVQ>? MlTzNlQhcA>? NIDv[GlKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MYOyN|A4QTB6Mx?=
A375 NYDSV5ZrSXW2b4DoZYd6KEG|c3H5 M1jtWlExKG6P Mlr2NVIhcA>? NUOyWG84UW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> MXSyN|A4QTB6Mx?=
BLM M3Xnd2F2fG:yaHHnfUBCe3OjeR?= NUTwXWEzOTBibl2= MWexNkBp NX7jU206UW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> MWWyN|A4QTB6Mx?=
H1299 NF71SmpCeG:ydH;zbZMhSXO|YYm= MV[4NEBvVQ>? NVvldJVOOjRiaB?= NF3ITVlFVVOR MmnoV4Vve2m2aYrld{BPW0OOQzDj[YxteyC2bzDNV2Mu\GW{aY\l[EBqSzlvaX7keYNm\CCjcH;weI9{cXN? NYThdJZPOjV|MkO2PVM>
Hut-78 NIrvS4pHfW6ldHnvckBCe3OjeR?= NFTyOIQyODBibl2= NVrSc|U4OjRiaB?= MkTVSG1UVw>? MonSSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w MnLVNlU3QDF|M{W=
H9 MmPDSpVv[3Srb36gRZN{[Xl? NETNenAyODBibl2= M{DUUVI1KGh? NVP0WWFKTE2VTx?= NW\nfnN1TG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMTDlfJBz\XO|aX;u NYPoS2FKOjV4OEGzN|U>
HH M2DvRmZ2dmO2aX;uJGF{e2G7 MkTSNVAxKG6P MYeyOEBp Mmq5SG1UVw>? NVvi[Y04\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u M2HwdVI2PjhzM{O1
Hut-78 NYP4bXA3VWmpcnH0bY9vKEG|c3H5 M4fnc|ExOCCwTR?= MV[yOEBp NWj2Sol7TE2VTx?= NVnBeZFIWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mwKS=> NHLofVIzPTZ6MUOzOS=>
HH MlXxUYloemG2aX;uJGF{e2G7 NWi5N|BCOTByIH7N MYiyOEBp NGXwVY9FVVOR NITHUVJT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUGl M3;MbVI2PjhzM{O1
U937 MXHGeY5kfGmxbjDBd5NigQ>? NWiwO414OTByIH7N NVTRZ|QxPiCq NEDxWmNKdmS3Y3XzJGlNNThiZYjwdoV{e2mxbjDpckBNWFNvc4TpcZVt[XSnZDDVPVM4KG2jY4LvdIhi\2W| NVj4[FE1OjV5OUG0O|c>
human PBMC NFPFZoJHfW6ldHnvckBCe3OjeR?= NX3jUWh4OTByIH7N MVOyOEBp NHe0U3JKdmS3Y3XzJGlNNThicnXs[YF{\Q>? NFT0[VMzPTd7MUS3Oy=>
ES6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;STow2UUN3ME2wMlAxOjFibl2= NXm1[VlrW0GQR1XS
SK-UT-1 M4XKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fncmlEPTB;MD6xOlMhdk1? NYW3PFJMW0GQR1XS
SH-4 M37yVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMUezJI5O NFHuWFBUSU6JRWK=
TE-9 M3qxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXobWlKSzVyPUCuNVgzKG6P M3SzenNCVkeHUh?=
A253 M1rxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPNVZRKSzVyPUCuNlA5KG6P NFH4NnNUSU6JRWK=
no-10 MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTVbHJZUUN3ME2wMlIyKG6P MYTTRW5ITVJ?
MMAC-SF M1HXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LBRWlEPTB;MD6yNVYhdk1? NVnpUGJrW0GQR1XS
A101D NEnzdGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;NeGpKSzVyPUCuNlI2KG6P M4n6U3NCVkeHUh?=
NTERA-S-cl-D1 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMkSzJI5O Mn;2V2FPT0WU
8-MG-BA M1fDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMkWgcm0> M2PMZnNCVkeHUh?=
KNS-42 M3jQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjQXnpKUUN3ME2wMlI2QCCwTR?= M1LVcHNCVkeHUh?=
LXF-289 NXW5[W1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\ifWlEPTB;MD6yOlkhdk1? NX3TVVJTW0GQR1XS
OVCAR-4 NWLaTVdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTuR5VKSzVyPUCuNlg6KG6P NHPJNHJUSU6JRWK=
LOUCY NEH4c2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HyVmlEPTB;MD6yPVMhdk1? MkDmV2FPT0WU
BB65-RCC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwM{C0JI5O NFrmVlZUSU6JRWK=
D-542MG NHPtSXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnkb2RKSzVyPUCuN|I6KG6P Ml2yV2FPT0WU
ONS-76 NXj1SJFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\IWmlEPTB;MD6zN{BvVQ>? M3nRfXNCVkeHUh?=
BB30-HNC NGPyPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwM{O1JI5O Mn;LV2FPT0WU
KS-1 NGH0fXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[2ZXFKSzVyPUCuN|Qhdk1? MoDSV2FPT0WU
A388 MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwM{W2JI5O NH\qUFlUSU6JRWK=
ES8 NI\IZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzXT49KSzVyPUCuOEBvVQ>? M3Lo[HNCVkeHUh?=
MZ2-MEL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPHOGJKSzVyPUCuOFA4KG6P M1XHS3NCVkeHUh?=
HCC2998 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf6eo5KSzVyPUCuOFEzKG6P MmrPV2FPT0WU
D-247MG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K2S2lEPTB;MD60NVMhdk1? NWnxT|NVW0GQR1XS
ACN M3HVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL3TWM2OD1yLkSxO{BvVQ>? MmHJV2FPT0WU
LB2518-MEL M{HQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXrdXRKSzVyPUCuOFI2KG6P MVvTRW5ITVJ?
ES1 MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rDZmlEPTB;MD60N{BvVQ>? NVzCdHc3W0GQR1XS
HCE-T M4fONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X0emlEPTB;MD60N|khdk1? M4Tk[3NCVkeHUh?=
OS-RC-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7BTWM2OD1yLkS0JI5O NWLwNWt1W0GQR1XS
MFH-ino NFzPSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDLTWM2OD1yLkS0N{BvVQ>? MoTrV2FPT0WU
OCUB-M NEPWVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yxSmlEPTB;MD60OFchdk1? NVOzUIJjW0GQR1XS
CP66-MEL MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLVeYN7UUN3ME2wMlQ4OyCwTR?= MUTTRW5ITVJ?
LB771-HNC NGLjfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M122ZmlEPTB;MD60O|Qhdk1? NWPiSZc1W0GQR1XS
DSH1 NHXkNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwNEigcm0> MX3TRW5ITVJ?
HUTU-80 M2mx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfhdo9KSzVyPUCuOVM{KG6P NFLF[Y5USU6JRWK=
CESS NVjVPHVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnZUI84UUN3ME2wMlU{QCCwTR?= Mo\ZV2FPT0WU
NCI-H747 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwNUO5JI5O M3XPNHNCVkeHUh?=
HT-144 M3HYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnOVIplUUN3ME2wMlU4PiCwTR?= M32zcXNCVkeHUh?=
COLO-829 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwNkG0JI5O MnLNV2FPT0WU
A4-Fuk NU\nWlFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwNkKzJI5O NF6wXFlUSU6JRWK=
GI-ME-N NXzLOWhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle2TWM2OD1yLk[zOEBvVQ>? MUHTRW5ITVJ?
LB831-BLC NWnhSZZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn5R45CUUN3ME2wMlY1OSCwTR?= MY\TRW5ITVJ?
HOP-62 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDuTWM2OD1yLk[0O{BvVQ>? NFX1SWZUSU6JRWK=
BB49-HNC M3zPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfsRVdKSzVyPUCuOlUzKG6P NUHTSmNFW0GQR1XS
D-336MG NVT0TW14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[0dGlEPTB;MD62OVchdk1? M1Pjb3NCVkeHUh?=
TK10 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNke5JI5O M332bXNCVkeHUh?=
Ramos-2G6-4C10 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwNkmzJI5O MWnTRW5ITVJ?
LB373-MEL-D NUXoTWV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[0VpZKSzVyPUCuO{BvVQ>? NWrSVmdIW0GQR1XS
SF126 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwN{CxJI5O NVzkfWNlW0GQR1XS
UACC-257 M2Xhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7tTWM2OD1yLkexJI5O NWf1O2dMW0GQR1XS
KINGS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:wTWM2OD1yLkeyNkBvVQ>? MYPTRW5ITVJ?
LS-513 M1LIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn3SW9LUUN3ME2wMlc{QSCwTR?= M3HZ[XNCVkeHUh?=
GI-1 MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHMTWM2OD1yLke2OEBvVQ>? NXfGUVN3W0GQR1XS
ES7 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHmTWM2OD1yLke2OkBvVQ>? M2XU[XNCVkeHUh?=
LB2241-RCC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf1TWM2OD1yLkiwOEBvVQ>? MknpV2FPT0WU
D-263MG NWrOcYx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT3TWM2OD1yLkiwO{BvVQ>? NI\ndopUSU6JRWK=
SW684 NFfzT4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPlSGg2UUN3ME2wMlgzOSCwTR?= MVjTRW5ITVJ?
ML-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwOEKxJI5O M3L1cXNCVkeHUh?=
SK-LMS-1 NELZRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLVTWM2OD1yLki1OEBvVQ>? NGfMWWpUSU6JRWK=
TE-5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDtTWM2OD1yLki2OUBvVQ>? M{PNRXNCVkeHUh?=
QIMR-WIL MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrne2E1UUN3ME2wMlg5QSCwTR?= M{K5OXNCVkeHUh?=
NCI-H1355 M1G5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjnTWM2OD1yLki5OUBvVQ>? MVXTRW5ITVJ?
SNB75 MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwOUGyJI5O M1zPXXNCVkeHUh?=
RXF393 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP4TWM2OD1yLkmxOEBvVQ>? M2DveXNCVkeHUh?=
IST-MEL1 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwOUG3JI5O NILaTWdUSU6JRWK=
SF268 M3TnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO1TWM2OD1yLkmyN{BvVQ>? NWT1VZJkW0GQR1XS
KALS-1 NIPSSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvVN2VsUUN3ME2wMlkzPSCwTR?= MYXTRW5ITVJ?
HC-1 NXLE[4FrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\jTWlEPTB;MD65O|Uhdk1? MW\TRW5ITVJ?
SW872 M17B[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXNeVN6UUN3ME2wMlk6PiCwTR?= M2Dhd3NCVkeHUh?=
PSN1 NYK5dZV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfXbItKSzVyPUGuNFEhdk1? NFWzWpZUSU6JRWK=
TE-1 M2TPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLPbYl5UUN3ME2xMlA{KG6P MX3TRW5ITVJ?
TE-10 M4D6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPNTWM2OD1zLkCzJI5O NHvRUVNUSU6JRWK=
RKO M2\zU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjPTWM2OD1zLkC2JI5O MoXEV2FPT0WU
LC-2-ad NYrLdFZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfsS4liUUN3ME2xMlA5KG6P M1n3RXNCVkeHUh?=
SK-MM-2 NIDmdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;VRVBwUUN3ME2xMlA6KG6P M3L6XnNCVkeHUh?=
VA-ES-BJ NFKwcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwMEmgcm0> MlzFV2FPT0WU
MZ7-mel MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jncWlEPTB;MT6wPUBvVQ>? MXfTRW5ITVJ?
D-392MG MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC2ZlBkUUN3ME2xMlEhdk1? NHTSTGdUSU6JRWK=
CCRF-CEM MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjrT5huUUN3ME2xMlE{KG6P MnzCV2FPT0WU
EM-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS5fpNZUUN3ME2xMlE3KG6P NXKzVG1JW0GQR1XS
HAL-01 NETTbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvYclFqUUN3ME2xMlE5KG6P NV3JdoZ5W0GQR1XS
TE-8 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nNPWlEPTB;MT6xPUBvVQ>? MWfTRW5ITVJ?
NCI-H1882 MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHOzNHJKSzVyPUGuNkBvVQ>? MW\TRW5ITVJ?
Daudi MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[wW3hKSzVyPUGuNlIhdk1? NXSyN3VZW0GQR1XS
BL-41 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTZeFRKSzVyPUGuNlUhdk1? M3nyeXNCVkeHUh?=
SR MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn1S2hKSzVyPUGuNlUhdk1? M2HncXNCVkeHUh?=
KM12 M4C5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfhVpA{UUN3ME2xMlI4KG6P NVvVb|MyW0GQR1XS
K5 NH:5TG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfBe2ZKSzVyPUGuNlghdk1? MUjTRW5ITVJ?
A3-KAW MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\nd4tKSzVyPUGuNlghdk1? MlvTV2FPT0WU
CMK MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfmS45ZUUN3ME2xMlI6KG6P Mk\xV2FPT0WU
Calu-6 MlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX6bFRKSzVyPUGuNlkhdk1? M{fld3NCVkeHUh?=
IST-SL2 NGm5fYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1juSGlEPTB;MT6zNUBvVQ>? NUft[|JCW0GQR1XS
OPM-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2roNGlEPTB;MT6zN{BvVQ>? NGPnfmxUSU6JRWK=
DU-4475 NGHNRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTFwM{[gcm0> NGWyWVBUSU6JRWK=
ECC12 NGDEcmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LLNmlEPTB;MT6zO{BvVQ>? NGXRV|lUSU6JRWK=
L-540 MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7vXZh4UUN3ME2xMlM4KG6P M{Pme3NCVkeHUh?=
CAS-1 MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz3dYhKSzVyPUGuN|chdk1? NFjyNHBUSU6JRWK=
PF-382 MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzrbYlKSzVyPUGuOFchdk1? MmTXV2FPT0WU
LS-411N MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj2R5N{UUN3ME2xMlU{KG6P M2TYN3NCVkeHUh?=
NCI-H69 NFvM[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP3VYdIUUN3ME2xMlU1KG6P MmHIV2FPT0WU
NB12 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwNU[gcm0> NUTZXGNrW0GQR1XS
HEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HWU2lEPTB;MT62NUBvVQ>? Mn24V2FPT0WU
GCIY NFzoOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX1TWM2OD1zLk[yJI5O NHnBb3JUSU6JRWK=
EHEB NU\rdFd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnLVnpKSzVyPUGuOlchdk1? MkPsV2FPT0WU
TGBC1TKB NWK2dnBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDsR|Z{UUN3ME2xMlcyKG6P M2Pmd3NCVkeHUh?=
KURAMOCHI MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwN{Kgcm0> NYLaOGR7W0GQR1XS
U-266 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\5NJJKSzVyPUGuO|Yhdk1? NH\vVZpUSU6JRWK=
LC4-1 NYj5TWU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\YO2lEPTB;MT63PUBvVQ>? MlLiV2FPT0WU
NCI-H2126 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXexWnBXUUN3ME2xMlghdk1? NXnIR5BDW0GQR1XS
NCI-H1092 M2\vNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHlTWM2OD1zLkigcm0> NETpc5FUSU6JRWK=
GB-1 NF3PTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTFwOEGgcm0> MUfTRW5ITVJ?
MV-4-11 NWHXS4t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTrTWM2OD1zLkiyJI5O M{nKenNCVkeHUh?=
Becker MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljTTWM2OD1zLkizJI5O MnnsV2FPT0WU
MPP-89 NELSe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwOEmgcm0> NHTDe3JUSU6JRWK=
BE-13 NVL2WZJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfGOY0{UUN3ME2xMlk{KG6P NFXxUJNUSU6JRWK=
697 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwOUmgcm0> NYPlUmZbW0GQR1XS
NKM-1 MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXiTWM2OD1{IH7N NV76cIZUW0GQR1XS
NB13 M2HlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[4fnlKSzVyPUKgcm0> MlPWV2FPT0WU
LS-123 NUD3d3hIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TNVmlEPTB;Mj6wNkBvVQ>? NHLUN3lUSU6JRWK=
NB17 MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrP[ZFpUUN3ME2yMlA1KG6P NU\jd28yW0GQR1XS
LAN-6 NFrXUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJwMEWgcm0> MoPrV2FPT0WU
EW-24 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe1TGI1UUN3ME2yMlA5KG6P NIHzNZpUSU6JRWK=
NOS-1 NWfte5lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe1Z|hTUUN3ME2yMlEyKG6P M1j3cHNCVkeHUh?=
BL-70 NU\oXXZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLsS4pUUUN3ME2yMlEzKG6P NYDOU4JXW0GQR1XS
GT3TKB MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HRWGlEPTB;Mj6xNkBvVQ>? NV3YO|dPW0GQR1XS
HH NWHPbpduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\hbINXUUN3ME2yMlE{KG6P NUnZbXdHW0GQR1XS
KE-37 NWLsUG9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXBTWM2OD1{LkGzJI5O M2LSZ3NCVkeHUh?=
MOLT-4 M2m3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TOe2lEPTB;Mj6xN{BvVQ>? NHWxOZJUSU6JRWK=
EKVX Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwMUSgcm0> Mm\GV2FPT0WU
KGN NWXO[GszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TNRWlEPTB;Mj6xOUBvVQ>? NYq1OmxOW0GQR1XS
ES4 M2XGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrhTWM2OD1{LkG2JI5O M1zQfnNCVkeHUh?=
SJSA-1 NWnQWFFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDQTWM2OD1{LkKxJI5O MX\TRW5ITVJ?
KMOE-2 NIXpNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NImwdFlKSzVyPUKuNlMhdk1? MVrTRW5ITVJ?
NB5 NIDYRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTWN3pbUUN3ME2yMlI4KG6P NGj6cWZUSU6JRWK=
BC-1 NHvrbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPoTWM2OD1{LkOxJI5O NE\iSm9USU6JRWK=
NB10 M2fDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITx[4hKSzVyPUKuN|Ihdk1? MYXTRW5ITVJ?
RPMI-8226 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJwM{Wgcm0> NFK3[GNUSU6JRWK=
SCC-3 Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L6bGlEPTB;Mj6zO{BvVQ>? MoixV2FPT0WU
ARH-77 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7oTGFKSzVyPUKuN|ghdk1? MUfTRW5ITVJ?
NCI-H748 MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzVUGczUUN3ME2yMlM6KG6P MYDTRW5ITVJ?
KU812 NXm3PXc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnUTWM2OD1{LkSyJI5O MlmyV2FPT0WU
NCI-H64 NH3ZTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37OTGlEPTB;Mj60OEBvVQ>? MlHRV2FPT0WU
NB69 MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTvdWVQUUN3ME2yMlQ3KG6P MUDTRW5ITVJ?
KNS-81-FD NXH0VHJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny5TWM2OD1{LkS4JI5O M1vvcXNCVkeHUh?=
LB1047-RCC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJwNUegcm0> NGrM[mdUSU6JRWK=
EB-3 MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zTc2lEPTB;Mj62OkBvVQ>? NGjPc4lUSU6JRWK=
Mo-T NFT3UI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrYXlNKSzVyPUKuO|Qhdk1? NIjyS5ZUSU6JRWK=
EW-16 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[4VVBKSzVyPUKuO|Uhdk1? NUDlUGozW0GQR1XS
CTV-1 M4rFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnXZYpXUUN3ME2yMlghdk1? M1vWPHNCVkeHUh?=
ETK-1 MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnVXGhIUUN3ME2yMlg1KG6P MlPjV2FPT0WU
C2BBe1 M1PlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJwOEmgcm0> NWjkeHpkW0GQR1XS
MOLT-16 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXmTWM2OD1{Lki5JI5O M{jvOHNCVkeHUh?=
SW954 M1nGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XvT2lEPTB;Mj65JI5O MWDTRW5ITVJ?
HT M{fCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTNwMEKgcm0> MX7TRW5ITVJ?
KARPAS-299 MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK1TWM2OD1|LkC2JI5O M{OyZXNCVkeHUh?=
MONO-MAC-6 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDSXmdKSzVyPUOuNUBvVQ>? NXe1NHhZW0GQR1XS
CGTH-W-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHwTWM2OD1|LkGgcm0> MlvqV2FPT0WU
SK-PN-DW MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TWRWlEPTB;Mz6xOEBvVQ>? NHnU[WNUSU6JRWK=
CW-2 MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6zTWM2OD1|LkKxJI5O NYXX[lJOW0GQR1XS
SK-N-DZ MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNwMk[gcm0> NFv6OZFUSU6JRWK=
NEC8 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTNwM{Wgcm0> M3r2dXNCVkeHUh?=
LB996-RCC NVPveFdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTNwNDDuUS=> M{jz[nNCVkeHUh?=
DB M4G3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof1TWM2OD1|LkSxJI5O NVfi[ItKW0GQR1XS
TE-15 MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr4TWM2OD1|LkSzJI5O M2f6eHNCVkeHUh?=
COR-L88 MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTNwNEegcm0> NG\3OZpUSU6JRWK=
LAMA-84 NFjmPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXHZ4JKSzVyPUOuOFkhdk1? MnH5V2FPT0WU
MEG-01 M13mb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT4TWM2OD1|LkS5JI5O NF3iVmFUSU6JRWK=
LOXIMVI Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\KTWM2OD1|LkWgcm0> NWjnVmc1W0GQR1XS
RPMI-8402 M1HG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D0NGlEPTB;Mz61JI5O NFfENZlUSU6JRWK=
KARPAS-45 M2fEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\FTWM2OD1|LkW0JI5O MmLBV2FPT0WU
HCC1187 NGfW[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\wN|BKSzVyPUOuOVQhdk1? M1rCVHNCVkeHUh?=
MZ1-PC NYPnbGZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNwNUSgcm0> MkfkV2FPT0WU
no-11 MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jPU2lEPTB;Mz61OUBvVQ>? M2rsTHNCVkeHUh?=
EVSA-T NWrYZYJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfZOFZKSzVyPUOuOkBvVQ>? NXfa[ItFW0GQR1XS
DJM-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPKTWM2OD1|Lk[zJI5O Mk[xV2FPT0WU
COLO-684 Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKxSmN{UUN3ME2zMlY3KG6P NVf1VGFnW0GQR1XS
NMC-G1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwNkigcm0> MmnUV2FPT0WU
LC-1F NX3wRZZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXNPWpnUUN3ME2zMlc1KG6P M3TuT3NCVkeHUh?=
RL95-2 MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LWfmlEPTB;Mz63PUBvVQ>? NXrQU4NDW0GQR1XS
COLO-320-HSR NGnYXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv6TWM2OD1|LkmyJI5O NF3TUI5USU6JRWK=
RCC10RGB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LNN2lEPTB;Mz65N{BvVQ>? M3i1dHNCVkeHUh?=
HD-MY-Z MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO2NZBKSzVyPUOuPVMhdk1? MkL4V2FPT0WU
NCI-H2141 NYGzZm52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTRwMEWgcm0> NVX4fIluW0GQR1XS
K-562 NHXqfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn1doNUUUN3ME20MlEzKG6P Mo\ZV2FPT0WU
NCI-H1648 NXvXbZNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHU[lVjUUN3ME20MlE{KG6P NHvRWFdUSU6JRWK=
OMC-1 NWLQbmJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjC[4RCUUN3ME20MlE5KG6P NHrRPItUSU6JRWK=
LB647-SCLC NVexfGRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX1dVFFUUN3ME20MlIzKG6P NITiVFhUSU6JRWK=
TE-12 NXm5NI5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHqO2dKSzVyPUSuNlUhdk1? MVzTRW5ITVJ?
NOMO-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnUXXdKSzVyPUSuN|Mhdk1? MnfnV2FPT0WU
Raji MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vWTWlEPTB;ND60OkBvVQ>? NFzRTmZUSU6JRWK=
NALM-6 NH;WV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzJSIJpUUN3ME20MlQ6KG6P MUTTRW5ITVJ?
HL-60 NHjxNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfGW5pKSzVyPUSuOlchdk1? M3ew[HNCVkeHUh?=
IST-SL1 NHn5ZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTRwNkigcm0> NIDXT2pUSU6JRWK=
MHH-PREB-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTRwOE[gcm0> MVzTRW5ITVJ?
MHH-NB-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTRwOUGgcm0> MnrPV2FPT0WU
JiyoyeP-2003 NWjLUZFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\LT2lEPTB;NTDuUS=> NGq5ToFUSU6JRWK=
SBC-1 NHLHfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTVwMEGgcm0> NHe5UWFUSU6JRWK=
CHP-126 NUHoOYlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHDPY9rUUN3ME21MlA3KG6P NXLzRoxGW0GQR1XS
LU-139 MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j6NWlEPTB;NT6xN{BvVQ>? NYfrcIxXW0GQR1XS
NCI-SNU-5 M4m1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnlR4FyUUN3ME21MlE4KG6P NUTMeoVZW0GQR1XS
SW962 M1nkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELZeHBKSzVyPUWuNlEhdk1? NGfKN4hUSU6JRWK=
EW-1 NFzsWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPhTWM2OD13LkOxJI5O NXr5dYM6W0GQR1XS
NCI-H1417 M2O2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr6fXZKSzVyPUWuOVEhdk1? MXHTRW5ITVJ?
LU-65 MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7yTWM2OD13Lki0JI5O M2DTUXNCVkeHUh?=
D-502MG NUnpZZZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHyTWM2OD14LkO3JI5O NID5[2lUSU6JRWK=
BC-3 NFGzbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTZwNkGgcm0> NUHIXFBKW0GQR1XS
GDM-1 NIDTe5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTZwN{egcm0> NEnHXYdUSU6JRWK=
NCI-H2196 M1;xSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnlSphPUUN3ME22Mlghdk1? NXvpOHo2W0GQR1XS
NB1 NVSyRZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPBdpRXUUN3ME22Mlg5KG6P MUnTRW5ITVJ?
NCI-H345 M3jHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLLTWM2OD15LkKgcm0> NFv3bpFUSU6JRWK=
SU-DHL-1 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLUTWM2OD15LkK0JI5O NVLESYRHW0GQR1XS
JVM-2 M4XyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2S5fGlEPTB;Nz6yPEBvVQ>? NWnNXpg1W0GQR1XS
LU-134-A NWnON3BoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTdwM{mgcm0> NEfBVmZUSU6JRWK=
NCI-H1694 NYq2UZVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTdwNUigcm0> MlLJV2FPT0WU
NCI-SNU-16 MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTdwNkWgcm0> NYXIN45[W0GQR1XS
L-363 NFS4c25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{faZWlEPTB;Nz63JI5O NYfHNIgzW0GQR1XS
KG-1 MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTdwOUSgcm0> NVHz[mh[W0GQR1XS
MN-60 NWLzS3hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRThwMUSgcm0> M3yxTXNCVkeHUh?=
NB6 M2Ky[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRThwNEigcm0> Mk\BV2FPT0WU
MLMA MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe1XIlKSzVyPUiuPFUhdk1? MV3TRW5ITVJ?
ATN-1 MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf1ZnpKSzVyPUiuPFkhdk1? M4CzZnNCVkeHUh?=
SK-NEP-1 M{XHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLiTWM2OD17LkCxJI5O NUTNbmFGW0GQR1XS
DMS-114 MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:0fGlEPTB;OT62NkBvVQ>? M2rBfnNCVkeHUh?=
CTB-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTBTWM2OD17Lk[3JI5O NUXxcHV2W0GQR1XS
NCI-H2081 NVGzW|N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr1dYRKSzVyPUGwMlA6KG6P MnfvV2FPT0WU
ES5 M3e0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fmdWlEPTB;MUCuN|ghdk1? M1:yOnNCVkeHUh?=
HCC1599 M4nNXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPReIFKSzVyPUGxMlkyKG6P MljjV2FPT0WU
NCI-H23 NIDjd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7zflNKSzVyPUGyMlEzKG6P MkjmV2FPT0WU
NCI-H1581 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3ZTWM2OD1zMj6yPEBvVQ>? NXrqUHJ1W0GQR1XS
JVM-3 NHu3cphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF{Lkm5JI5O M3nZXHNCVkeHUh?=
NCI-SNU-1 Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\DW2tEUUN3ME2xN{4yQSCwTR?= MV7TRW5ITVJ?
NB7 M1\HR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L5UGlEPTB;MUWuPVIhdk1? Ml\yV2FPT0WU
JAR M37peGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjWXm9KSzVyPUG2MlE{KG6P M1e1UHNCVkeHUh?=
TGW NVrWcppbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\HVGlEPTB;MU[uOFghdk1? MljSV2FPT0WU
U-87-MG M3rOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHMd2lUUUN3ME2xOk44PiCwTR?= MoP5V2FPT0WU
NCI-H1436 NULmblN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF5LkCxJI5O NF7FeFFUSU6JRWK=
GOTO MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGW5SpFKSzVyPUG3MlA3KG6P M1nENHNCVkeHUh?=
COLO-800 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF5Lk[0JI5O NVryfYpqW0GQR1XS
MFM-223 NWHmcmpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn1TWM2OD1zNz65NUBvVQ>? MYfTRW5ITVJ?
EW-18 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF5Lkm2JI5O M1PYNnNCVkeHUh?=
NB14 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF5Lkm4JI5O NEf1eWRUSU6JRWK=
EB2 Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[1U2lEPTB;MUiuNFghdk1? M{G4S3NCVkeHUh?=
EoL-1- MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnNfWNKSzVyPUG4MlMyKG6P NYj2clY5W0GQR1XS
NCCIT NEjGRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF6LkO2JI5O NYPFSoJQW0GQR1XS
DG-75 NE\5[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTv[FBzUUN3ME2xPE43OSCwTR?= M2jKNXNCVkeHUh?=
HCC2218 M1rBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrYW4tKSzVyPUG5MlUhdk1? NVLXNG9xW0GQR1XS
TE-6 Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nwXGlEPTB;MkCuNFghdk1? NIPKT4NUSU6JRWK=
SF539 MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTFTWM2OD1{MD62O{BvVQ>? NXPucFZbW0GQR1XS
NCI-H446 MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7WdYRKSzVyPUKxMlE5KG6P NGjQ[phUSU6JRWK=
IST-MES1 M33GUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7ZXVZKSzVyPUKyMlc4KG6P NYTRNVhLW0GQR1XS
NCI-H82 M1PQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjTPWtFUUN3ME2yN{4xOiCwTR?= MWfTRW5ITVJ?
HCC2157 NIrESoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomyTWM2OD1{Mz6xN{BvVQ>? M3n2cXNCVkeHUh?=
EW-12 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJ|LkG3JI5O NHywZlJUSU6JRWK=
SIMA NFXxRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJ|LkO4JI5O MWfTRW5ITVJ?
DOHH-2 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzyTWM2OD1{Mz60OUBvVQ>? NGnifpNUSU6JRWK=
IM-9 MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ|LkW0JI5O NIfJSpNUSU6JRWK=
EC-GI-10 NGPiXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ2LkKzJI5O MWHTRW5ITVJ?
HDLM-2 NIXFWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWixVndxUUN3ME2yOE42PCCwTR?= NX[5UW1zW0GQR1XS
LS-1034 M{nBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ3Lke1JI5O Mmr5V2FPT0WU
REH NIjEWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ4LkSxJI5O MVLTRW5ITVJ?
LU-165 MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHudnVrUUN3ME2yOk44OiCwTR?= MVzTRW5ITVJ?
NH-12 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJ5Lk[3JI5O MVjTRW5ITVJ?
WSU-NHL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVizSmF5UUN3ME2yPE4{QSCwTR?= M3POdHNCVkeHUh?=
ECC4 NGnvdnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDNTWM2OD1{OD63PUBvVQ>? MUDTRW5ITVJ?
OCI-AML2 NVHlem1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJ7Lk[5JI5O MljYV2FPT0WU
EW-3 NWHG[YNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNyLkW5JI5O NH3sWVVUSU6JRWK=
NCI-H526 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vq[mlEPTB;M{KuOVQhdk1? M3fCT3NCVkeHUh?=
NCI-H719 NEHEVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTN2LkOxJI5O NEPYUI5USU6JRWK=
KARPAS-422 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTN3LkC0JI5O MYfTRW5ITVJ?
SK-MEL-1 NELpfHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULJVG5bUUN3ME2zOU4yPyCwTR?= M{XSfHNCVkeHUh?=
ES3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\RbWlEPTB;M{WuNVkhdk1? NHqwdJZUSU6JRWK=
UACC-812 NFnFXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOwcIdCUUN3ME2zOU41PCCwTR?= MXXTRW5ITVJ?
C8166 NXXLXnZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rvSWlEPTB;M{WuO{BvVQ>? NGPHW3FUSU6JRWK=
MDA-MB-134-VI M3LYb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTqPWZCUUN3ME2zOU45PyCwTR?= NXGwcVVSW0GQR1XS
D-283MED M1zOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K5VGlEPTB;M{euO|khdk1? NGHze|NUSU6JRWK=
SHP-77 NF2xSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT1SIJ3UUN3ME2zPE4xOyCwTR?= MnK3V2FPT0WU
NCI-H2227 M3HvV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTRyLkS5JI5O MmK4V2FPT0WU
SKM-1 M{Djemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;WWmlEPTB;NEKuOlMhdk1? M2jOb3NCVkeHUh?=
L-428 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HyfGlEPTB;NEOuPFYhdk1? NHPIWHVUSU6JRWK=
RPMI-6666 NH7qTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTR3Lki5JI5O MoLTV2FPT0WU
NCI-H716 NYD1W3ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[4TWM2OD12OD64NUBvVQ>? M1fzWXNCVkeHUh?=
DMS-79 NGruXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XOeWlEPTB;NUCuO|Ehdk1? NGPMRXJUSU6JRWK=
RS4-11 MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mor6TWM2OD13MD64PEBvVQ>? M2HJdHNCVkeHUh?=
NCI-H720 NYPD[pdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXUNYk5UUN3ME21NU4yOSCwTR?= NVTSS5ozW0GQR1XS
MC-CAR M1fRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jV[mlEPTB;NUGuOVIhdk1? M1LxWnNCVkeHUh?=
TALL-1 Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjLTWM2OD13Mz65NUBvVQ>? M1zXWXNCVkeHUh?=
NCI-N87 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrvNI9FUUN3ME21OE4yQCCwTR?= NYjsV4lHW0GQR1XS
P30-OHK NUjx[G1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PkemlEPTB;NUSuOlEhdk1? NEPVZVRUSU6JRWK=
LP-1 NFXZZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS0TWM2OD14MT6yPEBvVQ>? NEfJVlNUSU6JRWK=
YT NF[1T29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTZzLkigcm0> MWHTRW5ITVJ?
MRK-nu-1 M4PZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[2TmlEPTB;NkGuPFIhdk1? MVfTRW5ITVJ?
BT-474 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;xUGlEPTB;NkWgcm0> NEDYbIVUSU6JRWK=
NCI-H322M NUnQZXN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jlfWlEPTB;Nk[uNVEhdk1? MUfTRW5ITVJ?
NCI-H128 Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHoTWM2OD15ND63O{BvVQ>? MkjxV2FPT0WU
KMS-12-PE NHLzOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z0VWlEPTB;N{[uNlQhdk1? M{XGfnNCVkeHUh?=
KP-N-YS MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTd4Lke0JI5O NFS0TIdUSU6JRWK=
ALL-PO M3TmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDXTWM2OD15Nz62OkBvVQ>? NELPWoNUSU6JRWK=
EW-13 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTd5Lke2JI5O MXrTRW5ITVJ?
EW-11 NEXqNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTd6LkWyJI5O MnXGV2FPT0WU
SK-N-FI NETROFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7tephKSzVyPUiwMlIhdk1? M4D0XnNCVkeHUh?=
CAL-148 NYi1OoJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPNTWM2OD16MT64OEBvVQ>? MV\TRW5ITVJ?
RL NV21ZY1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDETWM2OD16Nj6wPUBvVQ>? MnTFV2FPT0WU
AM-38 M{\pPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2THUGlEPTB;OEiuNFghdk1? NVLKOYpUW0GQR1XS
RH-1 M1ziOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTl7Lki1JI5O Mn7OV2FPT0WU
NCI-H1770 M2exXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITkOoJKSzVyPUGwNk41QSCwTR?= M4WwUnNCVkeHUh?=
SIG-M5 NV6yR3h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LxWGlEPTB;MUC1MlA3KG6P MnfYV2FPT0WU
GR-ST NWPwSndWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NECzOFFKSzVyPUGxN{4{PCCwTR?= MVrTRW5ITVJ?
ST486 NHPJfGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFzND6wOkBvVQ>? NXPhclV3W0GQR1XS
NCI-H1650 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny5TWM2OD1zMUWuNlkhdk1? NYrQb3h7W0GQR1XS
MHH-CALL-2 NYX1OYQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DXOGlEPTB;MUG1Mlchdk1? NV64d5QzW0GQR1XS
BV-173 NU\ne3l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\VN2lEPTB;MUKyMlcyKG6P MYjTRW5ITVJ?
MC116 NFXSPVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC5TWM2OD1zNEiuPFUhdk1? MmDVV2FPT0WU
NCI-H524 NH\ERZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF3OT6xJI5O NVXiRmZuW0GQR1XS
SCLC-21H M3vn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i3O2lEPTB;MUW5MlQyKG6P MkLsV2FPT0WU
NCI-H1304 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF4OT6yNUBvVQ>? M37IRnNCVkeHUh?=
NCI-H510A M4rmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TlTGlEPTB;MUi1MlM4KG6P MWTTRW5ITVJ?
NCI-H209 NHW1UpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTF7Nj61NkBvVQ>? NV3heHJiW0GQR1XS
KM-H2 NV7vXZVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTTVHdRUUN3ME2xPVcvODVibl2= MYHTRW5ITVJ?
NCI-H1395 NIH2eIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJzMD6xN{BvVQ>? MkDtV2FPT0WU
NCI-H1155 MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfhdpBIUUN3ME2yN|AvOzJibl2= M4TqWnNCVkeHUh?=
COR-L279 NUfMc29sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXOcmNKSzVyPUK1Nk4yPyCwTR?= NYHWOFBxW0GQR1XS
NCI-H1299 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPncFV7UUN3ME2yOlEvPzFibl2= NHzqSYZUSU6JRWK=
EW-22 NUXqN|NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17KSWlEPTB;Mk[zMlc2KG6P NUT1ToFTW0GQR1XS
SK-MEL-2 Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e4dGlEPTB;MkixMlkhdk1? NEfkXVBUSU6JRWK=
KASUMI-1 M{P6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rsdGlEPTB;MkizMlA2KG6P M2PLZXNCVkeHUh?=
NCI-H187 NUCx[3RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\qUmlEPTB;Mki3MlA5KG6P NUXQc2NpW0GQR1XS
NCI-H2171 M1GzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHaTWM2OD1{OEiuPVIhdk1? NXL5XIxtW0GQR1XS
LNCaP-Clone-FGC NGq2cYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni5TWM2OD1{OUWuNlYhdk1? MX;TRW5ITVJ?
NCI-H1522 NHr3SmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq0d3liUUN3ME2zNFcvODVibl2= M{\0N3NCVkeHUh?=
SCH NFPz[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GyW2lEPTB;M{KyMlIzKG6P MVHTRW5ITVJ?
THP-1 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXm[GVKSzVyPUOyNk43KG6P NHr0TGlUSU6JRWK=
SNU-C1 Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHl[ZNKSzVyPUO2Nk4xQSCwTR?= MYfTRW5ITVJ?
CA46 NUfEUlBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG5WVhOUUN3ME2zO|MvPjNibl2= MonnV2FPT0WU
NCI-H1963 NXjjW455T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPvTWM2OD1|OE[uNVkhdk1? M4HCR3NCVkeHUh?=
DEL NXrEb|hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfXcohKSzVyPUO5NU4zPyCwTR?= MWDTRW5ITVJ?
TUR NGfpOndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M322fGlEPTB;M{m2MlYyKG6P MYHTRW5ITVJ?
NCI-H226 M{ftS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTRyMz6yN{BvVQ>? MXvTRW5ITVJ?
COLO-668 NHTZXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTRyMz61O{BvVQ>? M1P3cXNCVkeHUh?=
CPC-N M{HwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LoSmlEPTB;NECzMlc4KG6P M1XpNXNCVkeHUh?=
NCI-H889 NV7vXHpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKwTWM2OD12NkGuPVIhdk1? NEX3ToZUSU6JRWK=
J-RT3-T3-5 MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT5TWM2OD13M{KuOVchdk1? MVfTRW5ITVJ?
MSTO-211H MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknjTWM2OD13N{SuNlYhdk1? MmPOV2FPT0WU
SCC-15 M4i1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTZ4Nz60O{BvVQ>? MWHTRW5ITVJ?
SUP-T1 NFHSPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTZ6Nj6wOEBvVQ>? MYrTRW5ITVJ?
DMS-153 MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv5TWM2OD15NE[uPFMhdk1? NFH1ZXlUSU6JRWK=
MS-1 MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37XOmlEPTB;N{W5MlQzKG6P NEfacY9USU6JRWK=
TC-YIK M{KwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j3c2lEPTB;N{ixMlAyKG6P M36zZnNCVkeHUh?=
RPMI-8866 NYPNfGQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3Le4NiUUN3ME2xNFA3NjJ6IN88US=> MUjTRW5ITVJ?
KY821 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK4TWM2OD1zMEO2MlA1KM7:TR?= MVnTRW5ITVJ?
P31-FUJ NWHpVIpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFzMUKuO|Uh|ryP MX7TRW5ITVJ?
COLO-824 NH;lPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i1U2lEPTB;MUK2NU44QCEQvF2= NVfKNlBMW0GQR1XS
U-698-M M1vOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPaOXlKSzVyPUKyOlIvOTVizszN M{TIZXNCVkeHUh?=
TE-441-T NYO1bWM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzDU4VZUUN3ME2yOVIyNjdizszN NHmze5lUSU6JRWK=
IMR-5 NVf6SWRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvONVRlUUN3ME2zOFA6NjZ{IN88US=> MnjEV2FPT0WU
NCI-H1838 NHv5NItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnizTWM2OD12MUi2MlMzKM7:TR?= MlThV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID